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The results of two acute placebo-controlled, double-blind cross-over studies assessing the effect of Panax ginseng (G115) on blood glucose levels
are reported. In study 1, thirty participants received three treatments: placebo; 200 mg G115; 400 mg G115. In study 2, twenty-seven participants
received four treatments: placebo (0 mg ginseng and 30 mg saccharin); ginseng (200 mg ginseng and 30 mg saccharin); placebo–glucose (0 mg
ginseng and 25 g oral glucose); ginseng–glucose (200 mg ginseng and 25 g oral glucose). Blood glucose levels were measured at baseline (at
09.00 hours after an overnight fast) and then 60, 90 (study 1 only) and 120 min post-dose. Both studies demonstrated that G115 alone significantly
lowers fasting blood glucose levels. Conversely, in study 2 there was a significant drink £ ginseng interaction suggesting opposing glycaemic
effects of ginseng under fasting and raised blood glucose conditions. These data have implications for the use of ginseng in individuals with
poor gluco-regulation.
Panax: Ginseng: Acute: Placebo: Blood glucose: Hypoglycaemia: Healthy adults
The number of diagnosed diabetes sufferers continues to rise
exponentially (Mokdad et al. 2003) and the currently available
armamentarium is insufficient to halt the disease progression.
The majority of type 2 diabetes patients eventually require
insulin therapy (Turner et al. 2000), and it is estimated that
diabetes is likely to be the fifth leading cause of death globally
(Roglic et al. 2005). While the use of mainstream drugs is
advocated by some physicians, many patients are more
inclined toward the use of alternative therapies including
food supplements and herbal medicines (Shane-McWorter,
2005). Despite a lack of evidence for their safety and efficacy,
the use of herbal products increased substantially through the
1990s, with over 60 % failing to report the use of these pro-
ducts to their physician (Eisenberg et al. 1998).
‘Ginseng’ usually refers to the dried root of several species
in the plant genus Panax (Araliaceae family). The most widely
used is Panax ginseng (G115), which is indigenous to the Far
East. Other members of the genus include Panax quinquefo-
lius (American ginseng), Panax notoginseng and Panax japo-
nicus. Ginseng is known to have gluco-regulatory properties.
For example, a decrease in fasting blood glucose and
HbA1c was reported in type 2 diabetic patients following 8
weeks administration of a proprietary extract of Panax quin-
quefolius, taken 40 min before each meal (Vuksan et al.
2000b). Additionally, reductions in blood glucose levels
were reported during a standard oral glucose tolerance test
in diabetic patients following 3, 6 and 9 g Panax quinquefolius
and in healthy participants administered 1, 2 and 3 g (Vuksan
et al. 2000a,b, 2001). With regard to G115, reduced fasting
blood glucose levels and glycated Hb (HbA1c) were found
following 8 weeks administration to type 2 diabetic patients
(Sotaniemi et al. 1995). Similarly, 24 months of treatment
with G115 decreased HbA1c in type 2 diabetics (Tetsutani
et al. 2000). We report here the glycaemic results of two
studies that assessed the effects of single doses of G115 on
blood glucose levels in healthy volunteers.
Method
Two separate placebo-controlled, double-blind, crossover
studies were undertaken in healthy young adults. All partici-
pants were recruited through university advertisement. Prior
to participation each participant gave informed consent and
completed a medical health questionnaire. All participants
reported that they were in good health, and that they were
free from heart disorders, high blood pressure, respiratory dis-
orders, epilepsy, panic attacks and diabetes. Additionally, they
reported being free from ‘over the-counter’ treatments, illicit
social drugs and prescribed medications, with the exception,
for some female volunteers, of the contraceptive pill. All par-
ticipants self-reported they were in an overnight fasting state
and were alcohol-free for at least 12 h prior to the 09.00
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hours baseline blood glucose measurements (which were all
consistent with expected overnight fasting blood glucose
levels in healthy volunteers). Both studies were approved by
the Northumbria University Division of Psychology Ethics
Committee and conducted in accordance with the Declaration
of Helsinki.
In study 1, sixteen female and fourteen male participants
(mean age 22·6 (SD 5·46) years) received 200 mg ginseng,
400 mg ginseng and placebo on separate days. In study 2,
ten female and seventeen male participants (mean age
21·89 (SD 4·64) years) received four treatments: placebo
(0 mg G115 and 30 mg saccharin), ginseng (200 mg G115
and 30 mg saccharin), placebo–glucose (0 mg G115 and
25 g oral glucose) and ginseng–glucose (200 mg G115 and
25 g oral glucose) on separate days. Participants in the
second study received their capsule treatment (200 mg
G115 or 0 mg G115) at time-point zero and then 30 min
later, a 200 ml drink (20 ml sugar-free fruit cordial and
180 ml tap water) containing 25 g glucose or 30 mg saccharin.
The timing of administration of each treatment was selected
on the basis that ginseng’s gluco-regulatory effects are evi-
dent within 1 h of administration while glucose levels peak
at around 30 min post-ingestion. In both studies, treatments
were separated by a 7 d washout period and were counterba-
lanced across participants and days. Capillary blood glucose
levels were measured at baseline then 60 min, 90 min
(study 1 only) and 120 min post-dose (in study 2 the timings
were calculated from the ingestion of the ginseng or placebo
capsule treatment) utilising a Reflotron Plus diagnostic
machine and test sticks (Roche Diagnostics, Mannheim,
Germany). The reliability of the test has previously been con-
firmed (Price & Koller, 1988).
Results
Statistics
Prior to analysis of ‘change from baseline’ data, raw baseline
scores for the three treatment conditions (placebo, 200 mg,
400 mg) in study 1 and for all four treatment conditions in study
2 (placebo, ginseng, placebo–glucose, ginseng–glucose)
were subject to one-way repeated measures ANOVA using
the Minitab statistical package version 13.1 (Minitab Ltd,
Coventry, UK).
‘Change from baseline’ post-dose blood glucose levels
were analysed using the Minitab statistical package version
13.1. Following an initial repeated measures ANOVA
(study 1, treatment £ time of blood sample; study 2,
ginseng £ drink £ time of blood sample) a priori planned
comparisons were made between placebo and each of the
active treatments (200 and 400 mg G115) at each time-point
utilising t tests with MSError as an error term (Keppel,
1991). To ensure the overall protection level against Type I
error, comparisons were strictly planned prior to commence-
ment of the study, only probabilities associated with planned
comparisons were calculated, all planned comparisons were
two-tailed.
Baseline
There were no significant differences in baseline blood glu-
cose levels revealed in study 1 (F(2,58) 2·66, P¼0·08) nor
study 2 (F(3,78) 2·25, P¼0·09) (see Table 1).
Study 1
The initial repeated measure ANOVA (treatment £ time of
blood sample) revealed a significant main effect of treatment
on blood glucose level (F(2,116) 3·59, P¼0·034), but there
was no significant treatment £ time-point interaction (F(4,116)
1·49, P¼0·210). Planned comparisons comparing each treat-
ment to placebo at each time-point revealed that there were
significant reductions in blood glucose levels for both ginseng
treatments at all post-dose time-points relative to placebo
(Table 1): 200 mg led to reductions at 1 h post-dose (t116
3·31, P¼0·001), after 90 min (t116 3·65, P¼0·0003) and
120 min post-dose (t116 2·58, P¼0·01). The 400 mg treatment
also led to reductions at 1 h post dose (t116 3·42, P¼0·0007),
after 90 min (t116 3·57, P¼0·0004) and 120 min post-dose
(t116 5·50, P¼0·0000001).
Table 1. The effects of Panax ginseng (G115) on capillary blood glucose levels in healthy human volunteers‡
(Mean values with their standard errors)
Pre-dose baseline
blood glucose level
(mmol/l)
Post-dose change from baseline blood glucose level (mmol/l)
60 min 90 min 120 min
Mean SEM Mean SEM Mean SEM Mean SEM
Study 1 (n 30)
Placebo 5·336 0·211 20·076 0·248 0·034 0·258 0·013 0·216
200 mg G115 5·681 0·159 20·646*** 0·176 20·594*** 0·198 20·432* 0·182
400 mg G115 5·939 0·996 20·664*** 0·214 20·580*** 0·212 20·933*** 0·213
Study 2 (n 27)
Placebo 5·229 0·125 20·198 0·126 20·721 0·114
200 mg G115 5·462 0·112 20·630††† 0·096 20·708 0·121
Glucose (25 g drink) 5·338 0·153 1·739††† 0·206 20·923 0·156
G115–glucose 5·077 0·122 1·980††† 0·268 20·603 0·151
Mean values were significantly different from those of the study 1 placebo group: *P,0·05; ***P,0·001.
Mean values were significantly different from those of the study 2 placebo group: †††P,0·001.
‡ For details of procedures, see p. 639.
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Study 2
A repeated measure ANOVA (ginseng £ drink £ time of
blood sample) revealed a significant ginseng £ drink interaction
on capillary blood glucose levels (F(1,26) 5·26,P¼0·03). The pat-
tern of results, taken across the two post-dose measurements,
suggests that the co-administration of ginseng with glucose
served to further increase blood glucose levels (mean of both
time-points 0·688 mmol/l) as compared with glucose alone
(mean 0·407 mmol/l). Conversely, in the absence of a glucose
drink ginseng serves to further reduce blood glucose levels
(mean 20·669 mmol/l) as compared with the saccharin con-
dition (mean 20·458 mmol/l).
Planned comparisons, comparing each treatment with pla-
cebo at each time-point, revealed that the ingestion of oral glu-
cose alone (placebo–glucose condition; t26 9·40, P,0·001)
and in combination with 200 mg ginseng (ginseng–glucose
condition; t26 10·570, P,0·001) led to significantly increased
blood glucose levels at the 1 h post-dose measurement point
compared with placebo (Table 1). There were no significant
differences between the placebo–glucose and ginseng–glu-
cose conditions on blood glucose levels. However, following
the ingestion of ginseng alone (ginseng–placebo condition),
blood glucose levels were significantly reduced 1 h post-dose
(t26 2·096, P¼0·046).
Discussion
Both study 1 and study 2 demonstrated that a single acute dose
of G115 can significantly lower blood glucose levels in
healthy, overnight fasted volunteers. Additionally, study 2
revealed a significant interaction between the administration
of 25 g oral glucose drink and 200 mg ginseng. This significant
pattern of results suggests that in the absence of a glucose load
(i.e. in overnight fasting participants) a single dose of G115
(200 mg) resulted in a post-dose fall in circulating blood glu-
cose levels, relative to placebo. However, in the presence of
elevated glucose levels following an oral glucose drink, the
co-administration of ginseng was associated with further
raised blood glucose levels, relative to the glucose condition,
although no significant increase was revealed at any individual
time-point on the planned comparisons, relative to the
glucose condition. Both study 1 and study 2 are indicative
of G115’s gluco-modulating properties in young non-diabetic
participants.
It should be noted that in both studies baseline differences
were not significant; however, there was a trend for significant
differences (0·05 , P,0·1) in both studies. While it is feas-
ible that this may have contributed to the magnitude of the
treatment effects observed in study 1, where treatment effects
tended to be in the opposite direction to initial condition
effects, this was not the case for study 2. Therefore, it appears
that the present data represent real physiological effects of
G115 rather than a reflection of chance baseline differences
between the conditions. Clearly further replication of the pre-
sent findings are needed, as is more research directed at deli-
neating the glycaemic properties of G115 in healthy and
patient populations.
The present results are dissimilar to the recently reported
hypoglycaemic effects of a different ginseng species, Panax
quinquefolius, during standard oral glucose tolerance tests in
both diabetic and healthy participants (Vuksan et al.
2000a,b, 2001) and are inconsistent with two reports of
G115 being associated with significantly increased blood glu-
cose levels and insulin responses following a 75 g glucose load
(Sievenpiper et al. 2003, 2004) suggesting that different
Panax species produce differing glycaemic responses. With
regard to American ginseng (Panax quinquefolius), Vuksan
et al. (2000a) have suggested three possible mechanisms:
modulation of glucose disposal, glucose transport or insulin
secretion. The three are not mutually exclusive and the latter
two may both be mediated by increased NO production
(Roy et al. 1998; Spinas et al. 1998). The mechanisms respon-
sible for the glycaemic effects of Korean ginseng reported
here may reflect similar processes possibly with different
levels of insulin receptor binding reversibility (although the
biological plausibility of this speculative idea remains to be
investigated). The exact processes affected by this herbal
extract remain unknown and may reflect complex additive or
synergistic effects on several physiological systems involved
in gluco-regulation (see Scholey et al. 2005). Until further
research has delineated the mechanisms underlying ginseng’s
gluco-regulatory effects, generalisations should not be made
between the effects of different ginseng species. Sufferers
from diabetes and similar conditions should exercise caution
in the use of ginseng products.
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